Diagnostic criteria for osteoporosis should not be expanded

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 4, 2015, Pages 236-238

  Schousboe, John T ^a   Ensrud, Kristine E ^b,c,d  

^a PARK NICOLLET INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; COLLAGEN TYPE 1; DENOSUMAB; HYDROXYAPATITE; RISEDRONIC ACID;

BONE DENSITY; BONE MICROARCHITECTURE; BONE STRUCTURE; COPING BEHAVIOR; DISEASE CLASSIFICATION; DISTRESS SYNDROME; DRUG EFFICACY; FALLING; FOREARM FRACTURE; FRAGILITY FRACTURE; GROUPS BY AGE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; NOTE; OSTEOPOROSIS; PRIORITY JOURNAL; RISK; RISK BENEFIT ANALYSIS; RISK FACTOR; SPINE FRACTURE; AGED; FEMALE; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 84925233323     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00050-9     Document Type: Note

References (14)

1. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994, 843:1-129. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.
2. Official Positions International Society for Clinical Densitometry. http://www.iscd.org/documents/2014/02/2013-iscd-official-position-brochure.pdf.
3. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001, 286:2815-2822.
4. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014, 25:1439-1443.
5. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 2009, 24:675-680.
6. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 2010, 25:1506-1511.
7. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148:197-213.
8. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012, 27:211-218.
9. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007, 22:135-141.
10. Benhamou CL Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007, 74:39-47.
11. Tosteson AN, Melton LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19:437-447.
12. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
13. Ostbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL Is there time for management of patients with chronic diseases in primary care?. Ann Fam Med 2005, 3:209-214.
14. Reventlow SD, Hvas L, Malterud K Making the invisible body visible. Bone scans, osteoporosis and women's bodily experiences. Soc Sci Med 2006, 62:2720-2731.